نتایج جستجو برای: hyperphosphatemia

تعداد نتایج: 1216  

Journal: :Journal of the American Society of Nephrology : JASN 2009
Olivier Moranne Marc Froissart Jerome Rossert Cedric Gauci Jean-Jacques Boffa Jean Philippe Haymann Mona Ben M'rad Christian Jacquot Pascal Houillier Benedicte Stengel Bruno Fouqueray

Chronic kidney disease (CKD) guidelines recommend evaluating patients with GFR <60 ml/min per 1.73 m(2) for complications, but little evidence supports the use of a single GFR threshold for all metabolic disorders. We used data from the NephroTest cohort, including 1038 adult patients who had stages 2 through 5 CKD and were not on dialysis, to study the occurrence of metabolic complications. GF...

2011
Ai Peng Tianfu Wu Caihong Zeng Dinesh Rakheja Jiankun Zhu Ting Ye Jack Hutcheson Nosratola D. Vaziri Zhihong Liu Chandra Mohan Xin J. Zhou

BACKGROUND Dysregulation of phosphate homeostasis as occurs in chronic kidney disease is associated with cardiovascular complications. It has been suggested that both hyperphosphatemia and hypophosphatemia can cause cardiovascular disease. The molecular mechanisms by which high or low serum phosphate levels adversely affect cardiovascular function are poorly understood. The purpose of this stud...

2014
Yogesh NV Reddy Varun Sundaram Georgi Abraham Prethivee Nagarajan Yuvaram NV Reddy

There has been an exponential increase in the incidence of diabetes and hypertension in India in the last few decades, with a proportional increase in chronic kidney disease (CKD). Preventive health care and maintenance of asymptomatic chronic disease such as CKD are often neglected by patients until they become symptomatic with fluid retention and uremia. Management of hyperphosphatemia in CKD...

Journal: :Journal of the American Society of Nephrology : JASN 2001
M Cozzolino A S Dusso E Slatopolsky

Cardiovascular events are the most frequent cause of death in patients with chronic renal failure (1–2). Heterotopic calcification of blood vessel walls occurs frequently with advanced age, atherosclerosis, and diabetes mellitus (3). In chronic renal failure, autopsy (4–5) and clinical investigations (6) have documented a higher prevalence of coronary plaques in dialyzed patients compared with ...

Journal: :Seminars in nephrology 2004
Hirotoshi Morii Tayuki Inoue Takaaki Nishijima Takashi Tomokuni Takatoshi Ishikawa Kenji Moriya Nobuaki Kawai Hiroyuki Araki Misa Horio Tsutomu Shigeoka Koji Tani Tadashi Yamaguchi Noboru Kubodera

In chronic renal failure, hyperphosphatemia, hypocalcemia, hyperparathyroidism, reduced activation of vitamin D, decreased level of calcium-sensing receptor, osteitis fibrosa, and osteomalacia are features related to calcium abnormalities. Hyperparathyroidism is a risk factor for survival of hemodialysis patients as well as hypoparathyroidism, which is another feature in hemodialysis patients. ...

2007
Yonggu Lee Taiyon Koo Joo-Hark Yi Jung-Hye Choi Sang-Woong Han Ile-Kyu Park Ho-Jung Kim

Hyperphosphatemia is an unusual manifestation in patients with multiple myeloma without a significantly reduced glomerular filtration rate. Serum phosphate may be falsely elevated when a large amount of paraproteins is present in the serum, because ultraviolet light absorbance is elevated with the phosphomolybdate ultraviolet assay, which is most commonly used for serum phosphate measurement. T...

Journal: :iranian journal of pharmaceutical sciences 0
naser tavakoli department of pharmaceutics abbas jafarian department of pharmacology, faculty of pharmacy and pharmaceutical sciences, isfahan university of medical sciences, isfahan, iran farzin najmi department of pharmaceutics

calcium acetate is used as an oral phosphate binder to control hyperphosphatemia in patients with chronic renal failure. compared to calcium carbonate, control of hyperphosphatemia can be achieved at lower calcium administration with calcium acetate which likely reduces the risk of hypercalcemia. in this study, various formulations of calcium acetate tablets were prepared and their disintegrati...

Journal: :Jornal brasileiro de nefrologia : 'orgao oficial de Sociedades Brasileira e Latino-Americana de Nefrologia 2011
Aluizio Barbosa de Carvalho Lilian Cuppari

2.2 Na DRC estágios III e IV, a ingestão dietética de P deverá ser mantida em valores que atendam a recomendação de proteínas entre 0,6 e 0,8 g/kg/dia, porém não superior a 700 mg/dia se o P estiver acima dos valores normais e/ou se o paratormônio (PTH) estiver acima do nível recomendado para o estágio da DRC (Opinião). 2.3 Na DRC estágio V D, a ingestão dietética de P deverá estar entre 800 e ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید